Cargando…

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer

Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in breast cancer treatment. Targeting HER2 gene amplification is one of the greatest successes in oncology, resulting in the use of a wide array of HER2-directed agents in the clinic. The discovery of HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eli, Lisa D., Kavuri, Shyam M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771739/ https://www.ncbi.nlm.nih.gov/pubmed/36627899 http://dx.doi.org/10.20517/cdr.2022.48

Ejemplares similares

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

The uncharted role of HER2 mutant alleles in breast cancer
por: Kalra, Rashi, et al.
Publicado: (2023)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2022)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
por: Shishido, Stephanie N., et al.
Publicado: (2022)

Neratinib for breast cancer
Publicado: (2019)

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
por: Takeda, Tatsuaki, et al.
Publicado: (2020)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2
por: Liu, Zundong, et al.
Publicado: (2021)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
por: Abraham, Jame, et al.
Publicado: (2019)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program
por: Pellerino, Alessia, et al.
Publicado: (2022)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis
por: Nagpal, Aadya, et al.
Publicado: (2019)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k2jovfsquuflkvs51nbf1qo1o3